secwatch.observer — SEC 8-K summary
======================================

Issuer:     MANNKIND CORP (MNKD)
CIK:        0000899460
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0000950170-25-103532
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MannKind Q2 revenue $76.5M (+6% YoY); Afrezza sBLA for pediatric population submitted
--------------------------------------------------------------------------------

- Total revenues $76.5M, up 6% YoY; net income $0.7M versus net loss $2.0M in Q2 2024.
- Afrezza sales $18.3M (+13% YoY); royalties from Tyvaso DPI $31.2M (+22%).
- Non-GAAP net income $13.9M ($0.05/share) vs $14.3M ($0.05) in Q2 2024.
- Submitted sBLA for Afrezza in pediatric patients (ages 4-17); FDA decision expected early Q4 2025.
- ICoN-1 trial of MNKD-101 enrollment ahead of schedule; interim target of 100 patients expected early Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/0000950170-25-103532-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/899460/000095017025103532/mnkd-20250806.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-103532

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer